Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Virus Diseases 1Lymphoma 1Infections 1Epstein-Barr Virus Infections 1

Interventions

threonic acid 1plerixafor 1ethanolamine oleate 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tenofovir 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Pneumococcal Vaccines 1Peripheral Blood Stem Cell Transplantation 1Pentetic Acid 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Melphalan 1Magnesium Sulfate 1Lenalidomide 1Human Papillomavirus Recombinant Vaccine nonavalent 1Filgrastim 1Ethanol 1Edetic Acid 1ER 30346 1Cyclophosphamide 1Carmustine 1Anidulafungin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Infections × Tenofovir × Clear all
NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

The Affiliated Hospital of Xuzhou Medical University

Phase 1/2 Not yet recruiting
30 enrolled

Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡